Synthesis, characterization and inhibitor properties of benzimidazolium salts bearing 4-(methylsulfonyl)benzyl side arms


GÜZEL A., NOMA S. A. A. , ŞEN YÜKSEL B., Kazancı A., Taskin-Tok T., KOLAÇ T., ...More

Journal of Molecular Structure, vol.1273, 2023 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 1273
  • Publication Date: 2023
  • Doi Number: 10.1016/j.molstruc.2022.134320
  • Journal Name: Journal of Molecular Structure
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, INSPEC
  • Keywords: Acetylcholinesterase, Benzimidazolium salt, Molecular docking, Single-crystal, Sulfonyl, Xanthine oxidase
  • Bursa Uludag University Affiliated: Yes

Abstract

© 2022 Elsevier B.V.Herein, a series of N-heterocyclic carbene (NHC) precursors bearing sulfonyl moieties was prepared. 1-(4-(methylsulfonyl)benzyl)-3-alkylbenzimidazolium chloride salts were synthesized with the reaction of 1-alkylbenzimidazoles with 4-(methylsulfonyl)benzyl chloride. These compounds were characterized by using 1H NMR, 13C NMR, FT-IR spectroscopy and elemental analysis techniques. Molecular and crystal structures of compounds 2e and 2j were determined by using the single-crystal X-ray diffraction method. Furthermore, enzyme inhibitory properties of benzimidazolium salt were tested against xanthine oxidase (XO) and acetylcholinesterase (AChE), then determined the IC50 value range of XO were determined from 0.218 to 1.927 µM, while the IC50 for AChE were determined from 1.328 to 5.22. Docking applications were used by using AutoDock4 in order to define the binding pose of the selected compounds, (2c, 2d and 2g) and also to visualize the correlation of the generated optimal complexes. It is found that the compound 2g has good binding affinity (-11.24 kcal/mol) against AChE, on the other side, compound 2c shows the lowest binding energy (-8.32 kcal/mol) for the XO target. These findings and the defined compounds could be as potential agents to develop effective medicine for AChE and XO in the future.